Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has entered into a clinical trial agreement with Mayo Clinic to evaluate SNS01-T as a treatment for multiple myeloma.
Subscribe to our email newsletter
The study is a dose-escalation, open-label, multiple-dose trial to evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.
The study aims for twice-weekly dosing of patients for 6 weeks followed by a safety data review period before escalating to a higher dose level in a new group of patients.
The principal investigator in the study at Mayo is John Lust.
Senesco president and CEO Leslie Browne said they have collaborated for several years with Lust to study SNS01-T and its predecessors before selecting their lead candidate.